Cempra (CEMP) Announces Date for FDA Meeting on Solithromycin as CABP Treatment
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Cempra, Inc. (Nasdaq: CEMP) announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Antimicrobial Drugs Advisory Committee on November 4, 2016 in Silver Spring, Maryland to discuss the safety and efficacy of solithromycin to treat community-acquired bacterial pneumonia (CABP).
Cempra conducted two pivotal Phase 3 global registration trials of solithromycin. The first study was conducted with solithromycin oral capsules, and the second study tested intravenous (IV) solithromycin progressing to oral solithromycin. Both Phase 3 studies met their primary endpoints that were aligned with FDA guidance.
Solithromycin was granted qualified infectious diseases product (QIDP) designation which entitled the new drug applications (NDAs) to eight month priority reviews, resulting in PDUFA dates of December 27, and December 28, 2016, respectively, the oral and intravenous NDAs.
“Antimicrobial resistance is an urgent public health threat and we believe that the strong data we have seen with solithromycin in clinical trials supports its approval as a new IV and oral antibiotic that would meet an important unmet need in the treatment of both in-patient and out-patient CABP,” said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.
“We look forward to the November 4 discussion with the advisory committee, and continued dialogue with the FDA, as we progress towards the solithromycin PDUFA dates at the end of the year,” Fernandes added.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ARIAD Pharma (ARIA) Presents Strong Data from Brigatinib ALTA Trial in ALK+ NSCLC
- ITUS Corp. (ITUS) Announces Prelim. Data from Cchek Cancer Study; Strong Sensitivity, Specificity Data Noted
- Nu Skin Enterprises (NUS) CEO Hunt to Depart in mid-2017; Transition Plan Announced
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesPDUFA, AdCom
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!